Paediatric pneumococcal disease in Central Europe.

Area of Science:

• Epidemiology
• Infectious Diseases
• Public Health

Background:

• Streptococcus pneumoniae causes significant global child illness and death.
• Pneumococcal conjugate vaccines (PCVs) are available but their introduction requires accurate disease burden data.
• Central Europe's pneumococcal disease burden requires updated epidemiological assessment.

Purpose of the Study:

• To appraise the pneumococcal disease epidemiological situation in 11 Central European countries.
• To evaluate the incidence and fatality rates of pneumococcal infections in the region.
• To identify data gaps and recommend surveillance improvements for informed vaccination policy.

Main Methods:

• Data synthesis from the 12th Central European Vaccine Advisory Group (CEVAG) meeting.
• PubMed literature review using specific search terms for pneumococcal diseases and Central European countries.
• Analysis of disease incidence and fatality rates, particularly in young children.

Main Results:

• Pneumococcal disease incidence in Central Europe appears lower than previously reported for Europe overall.
• The highest risk group for pneumococcal disease is infants aged 0-2 years.
• Fatality rates from invasive pneumococcal infections in children under five can reach up to 40%.

Conclusions:

• A lack of standardized surveillance hinders comprehensive country-specific data on pneumococcal disease burden.
• Accurate evaluation of the pneumococcal disease burden in Central Europe necessitates standardized, active surveillance systems.
• Improved surveillance is crucial for addressing the need for and optimizing the use of pneumococcal vaccination.